Stock Profiles
EcoloCap Solutions, Inc. (OTC-BB: ECOS)
EcoloCap Solutions, Inc., through its subsidiaries Micro Bubble Technologies Inc., K-MBT Inc., and EcoloCap Solutions Inc. Canada, provides an integrated and complimentary network of environmentally focused technology companies that utilize advanced nanotechnology to design, develop, manufacture and sell cleaner alternative energy.
Their portfolio of products and service include its Carbon Nano Tube Battery (CNT-Battery), a rechargeable battery that surpasses the performance capabilities of any existing battery, M-fuel, an innovative suspension fuel for non-gasoline applications that exceeds all conventional fuels’ cost and efficiencies, and carbon credit trading consultancy services.
Learn More about EcoloCap Solutions, Inc. (ECOS)
Provectus Pharmaceuticals, Inc. (OTC-BB: PVCT)
Provectus Pharmaceuticals develops oncology and dermatology therapies primarily using the Rose Bengal compound. The company’s lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects, while it also has a topic treatment, PH-10, for atopic dermatitis.
The company’s PV-10 therapy recently finished Phase II trials and has demonstrated both safety and efficacy for metastatic melanoma, while it is being separately tested for breast cancer and metastatic liver cancer. Going forward, the company does not anticipate needing additional capital, and will seek out a development partner to provide additional funding.
Learn More about Provectus Pharmaceuticals, Inc. (PVCT)
Sinobiopharma, Inc. (OTC-BB: SNBP)
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. The company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
Recently, the company announced that 23 generic drugs for which it has production rights are listed in China’s National Essential Drugs list, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China. Under the country’s new healthcare reform plan, 90% of China’s citizens will be covered by universal healthcare by the year 2010.